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Background: Celiac disease (CD) is a common systemic disease related to a permanent intolerance to gluten and
is often associated with different autoimmune and neurological diseases. Its mean prevalence in the general
population is 1-2% worldwide. Our aim was to study the prevalence of celiac disease in a prospective series of
Multiple Sclerosis (MS) patients and their first-degree relatives.
Methods: We analyzed the prevalence of serological, histological and genetic CD markers in a series of 72 MS
patients and in their 126 first-degree relatives, compared to 123 healthy controls.
Results: Tissue IgA-anti-transglutaminase-2 antibodies were positive in 7 MS patients (10%), compared to 3 healthy
controls (2.4%) (p < 0.05). OR: 5.33 (CI-95%: 1.074-26.425). No differences were found in HLA-DQ2 markers between
MS patients (29%) and controls (26%) (NS).
We detected mild or moderate villous atrophy (Marsh III type) in duodenal biopsies, in 8 MS patients (11.1%). We
also found a high proportion of CD among first-degree relatives: 23/126 (32%). Several associated diseases were
detected, mainly dermatitis 41 (57%) and iron deficiency anemia in 28 (39%) MS patients. We also found in them,
an increased frequency of circulating auto-antibodies such as anti-TPO in 19 (26%), ANA in 11 (15%) and AMA in 2
(3%).
Conclusions: We have found an increased prevalence of CD in 8 of the 72 MS patients (11.1%) and also in their
first-degree relatives (23/126 [32%]). Therefore, increased efforts aimed at the early detection and dietary treatment
of CD, among antibody-positive MS patients, are advisable.
Background
Multiple Sclerosis (MS) is a chronic disease of unknown
etiology, characterized by the presence of disseminated
demyelinating lesions in the central nervous system
(CNS), and associated with autoimmunity. Activated,
potentially autoimmune, T cells cross the blood-brain
barrier and produce inflammatory plaques and axonal
loss in the brain, spinal cord or optic nerves. The end
result is the accumulation of gliosis and demyelination
and areas in the CNS. MS affects about 1 ‰ of the
population worldwide.
Mainly occurs in young people, more often women.
The Relapsing-Remitting form of Multiple Sclerosis
(RRMS) makes up 80% of the total number of MS cases
and is characterized by intermittent episodes of relapses
and prolonged remissions. Clinically, patients display
episodes of acute neurological dysfunction, followed by
recovery and a symptom-free interval until the next out-
break. These recurrent events eventually lead to more
permanent neurological disabilities. Using an experi-
mental model of autoimmune encephalitis as a starting
point, immunomodulatory and immunosuppressive
therapies have then proved effective in preventing
relapses in MS patients, especially when performed early
in the course of the disease [1-7].
Celiac disease (CD) is a systemic autoimmune disorder
characterized by permanent intolerance to gluten in
genetically predisposed individuals. The genetic basis for
gluten intolerance is located in the region of chromo-
some 6 coding for HLA class-II [8-11]. Some patients
with RRMS show high levels of anti-tissue transglutami-
nase-2 (TGt-2) antibodies, which is an important serolo-
gical marker in the diagnosis of the disease [12]. Based
on this observation and on the possible association of MS
with other autoimmune processes, we have applied a
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Methods
Patients
We conducted a prospective observational study of a
consecutive series of 80 patients suffering from well-
established and clinically definite MS. They were
p r e v i o u s l yd i a g n o s e dw i t hR R M Sa n dc h e c k e du pa ta n
outpatient clinic for demyelinating disorders within the
Department of Neurology at the Central University Hos-
pital of Asturias (HUCA). This is an urban tertiary hos-
pital located in Northern Spain, serving an area with a
population of 250,000. Patients were enrolled during a
one-year period (January-December 2006). Of the initial
80 RRMS a total of 72, were included in this study (the
other 8 didn’t complete the study protocol).
MS patients with primary or secondary progressive
forms of the disease (PP or SP) were not included in the
study, because most of these patients were very physi-
cally disabled, in wheelchairs, and it would have been
very inconvenient for them to attend the necessary
check-ups.
We also included in this study a total of 126 first-
degree relatives of the 72 RRMS patients. We compared
the findings with a control group of 123 marrow blood
donors of the same area.
The study was approved by the Research and Ethics
Committee of the HUCA, following the principles
included in the modified Declaration of Helsinki.
All RRMS patients in this series were diagnosed on
the basis of medical history, neurological examination
and paraclinical positive tests, including Magnetic Reso-
nance Imaging (MRI), Cerebrospinal fluid (CSF) and
Visually Evoked Potentials (VEP), according to the 2005
McDonald criteria [13]. All cases also met the spatial
and temporal dissemination criteria.
Clinical parameters
At the time of inclusion in the study, RRMS patients
underwent a brain and spine MRI with intravenous
injection of 0.2 ml/kg body weight of gadolinium (Mag-
nevist™ 0.5 mmol/ml) as a contrast agent to assess
uptake. All subjects were studied and monitored by the
same neurologist (CHL), who followed-up with them at
least twice a year.
With regard to treatment, 48 of the patients were receiv-
ing immunomodulatory therapy. Four patients received
interferon beta-1a (30 mcg. IM/weekly), while 39 received
interferon beta-1a (22-44 mcg. SQ/3 days per week)
or interferon beta-1b (250 mcg SQ, on alternate days).
Five other patients received glatiramer acetate (20 mg
SQ/daily). No patient received immunosuppressive
therapy. The remaining 24 patients were not treated.
During relapses, subjects received hospital inpatient
treatment with methylprednisolone (500-1000 mg IV/
day for 3-5 days), except those with sensitive outbreaks,
who were treated as outpatients with oral prednisone at
a dose of 1 mg/kg/day for 1 week. In both cases, the
initial steroid therapy was progressively decreased
throughout the treatment period.
MS studies
MS disease activity was assessed by measuring the
annual relapse rates and the EDSS (Expanded Disability
Status Scale). The initial relapse rate value was calcu-
lated as the average over the two years preceding the
admission into the study. EDSS was assessed at the time
of admission into the study, leaving at least one month
between the most recent episode and the EDSS assess-
ment. The data on the number of relapses, their annual
rate, and EDSS were updated at every follow-up visit,
during the study period.
CD studies
All patients were invited to participate on a voluntary
basis in a screening test for CD associated with the diag-
nosed RRMS. In 90% of the cases, the patients accepted.
These subjects were referred to an outpatient Gastroen-
terology clinic specialized in the study of small intestine
diseases, which was located in the same hospital. All
consenting patients were evaluated by the same gastro-
enterologist (LR). Every patient underwent a series of
analytical assessments, which included serological and
CD genetic markers, together with an upper GI endo-
scopy with multiple duodenal biopsies.
Laboratory tests
Complete blood count tests including erythrosedimentation
rates (ESRs) were performed with an automated hematol-
ogy analyzer (Cell-DYN 3500 model R Abbott); complete
coagulation panels were also carried out with a coagulation
analyzer (ACL 3000, Menarini). Normal hemoglobin values
were in the 12-14 g/dl range, and cases of iron deficiency
anemia were defined according to WHO criteria, i.e. Hb <
13 g/dl in males and < 12 g/dl. in females. Normal white
blood cell count was set between 4-10 × 10
3/L and normal
platelet count was between 130-400 × 10
3/L.
Comprehensive analytical biochemistry tests were
performed on the blood samples, including analyses of
the following parameters: iron metabolism, including
serum iron levels; transferrin saturation index (TSI)
and serum ferritin. Normal values of serum iro were in
the 60-140 mcg/ml range, whereas the normal ferritin
values were 13-150 ng/ml. The TSI was considered
normal, for values ranging between 25-45%.
We also assessed liver function tests (LFTs) including
alkaline phosphatase (AP), aspartate aminotransferase
Rodrigo et al. BMC Neurology 2011, 11:31
http://www.biomedcentral.com/1471-2377/11/31
Page 2 of 7(AST), alanine aminotransferase (ALT), gamma glutamyl
transpeptidase (GGT) and bilirubin. The following mea-
surements were also performed: total serum calcium,
folate and vitamin B-12, serum creatinine, total choles-
terol (with normal values in the 150-240 mg/dl range),
high density lipoprotein (HDL), low density lipoprotein
(LDL) and triglycerides, urea, glucose, total protein,
albumin and acute phase reactants such as CRP (C-reac-
tive protein). The normal values of AST and ALT were
between 1-31 U/L. Immunoglobulins (IgG, IgA, IgM)
were quantified by nephelometry, and circulating levels
of the thyroid stimulating hormone (TSH, normal range:
0.25-5.0 mU/L) and the thyroid hormones (T3 and T4)
were also evaluated. Finally, an urinalysis with micro-
scopic examination of sediment was performed. Serum
levels of triglycerides and total cholesterol were deter-
mined using enzymatic tests and values were expressed
in mg/dl. All analytical studies were completed on a
Hitachi Modular automated analyzer SXA-PPBD
(Roche) using enzymatic or kinetic methods.
Serological markers of autoimmunity
The presence of anti-nuclear antibodies (ANA) and anti-
thyroid antibodies like anti-peroxidase (anti-TPO) were
measured routinely, and in those cases with altered
LFTs, the anti-mitochondrial antibody (AMA) was also
assessed. The determination of ANAs, anti-TPO and
AMAs, was conducted by indirect immunofluorescence
assay on the Hep-20-10 cell line (Euro-Immun, Lübeck,
Germany).
Serological markers of celiac disease
Tissue transglutaminase 2 (TGt-2) anti-IgA antibody
count was the only marker used; quantification was
achieved with the aid of a commercially available ELISA
kit (Phadia Diagnostics, Upsala, Sweden). We reported
as positive those tests with values > 2 U/ml, a threshold
considered to allow for a greater sensitivity in the gen-
eral population [14], and which we had already con-
firmed in a previous comparative study of several
commercial kits [15]
Genetic markers
To assess genetic susceptibility to CD two HLA-class II
markers, the HLA-DQ2 (DQA1*0501 and DQB1*0201)
and the HLA-DQ8 (DQA1*0301 and DQB1*0302) were
assayed, by using a Polymerase Chain Reaction (PCR)
with a commercially available kit (Protrans
® HLA Celiac
Disease Domino System, Protrans, Ketsch, Germany).
Duodenal biopsy studies
Upon approval of informed consent procedures by the
Hospital Ethics Committee, an upper endoscopy with
multiple duodenal biopsies (at least 4) was performed in
all the patients included in the study. Samples were rou-
tinely stained with Hematoxylin-Eosin (HE) and with
immunohistochemical CD3-specific stains, which are
routinely used to verify the presence of intraepithelial
lymphocytes (IEL). IELs were in turn quantified per 100
epithelial cells.
Duodenal biopsies were studied by two expert pathol-
ogists and classified into the following types: Stage 0:
Histologically normal duodenum; Stage 1: Increased IEL
infiltration with a total count > 25% of epithelial cells;
Stage 2: hyperplasia of crypts and/or diffuse chronic
inflammatory infiltrate at the level of the lamina propria;
Stage 3: villous atrophy, subdivided into three categories:
a) mild, b) moderate, and c) severe, according to the
anatomo-pathological classification for CD screening
previously described by Marsh in 1992 [16] and later
modified by Oberhuber et al. [17] in 1999.
We used neither gastric biopsies nor breath testing to
routinely determine the presence of Helicobacter pylori
infection in our patients.
Statistics
Descriptive statistics were used on continuous para-
meters: calculation of means, standard deviations, and
observed ranges. For qualitative variables, percentages
were used in the analyses. We determined the Chi-square
test for these categorical variables between non-paired
groups, using the exact Fisher’s test when necessary. The
odds ratio and CI-95% were also calculated. A p value <
0.05, was considered as statistically significant.
Results
Of the 72 RRMS patients included into the study, 60 (83%)
were women, giving a female-male ratio of 5/1. Their ages
ranged from 24 to 58 years old. The mean duration of
RRMS, the clinical activity, the number of patients receiv-
ing any type of immunomodulatory treatment, and the
percentage of fertility are shown in Table 1.
The clinical indicators of MS and the results of several
paraclinical tests are presented, including the presence
of oligoclonal bands (OCB) in the CSF, visual evoked
potentials (VEP) and somato-sensorial evoked potentials
Table 1 Clinical and demographic characteristics of RRMS
patients (n = 72)
Females, n (%) 60 (83)
Age in years, mean ± SD (range) 43 ± 10 (24-61)
RRMS duration in years, mean ± SD (range) 11 ± 6 (1-30)
Annual relapse rate, mean ± SD (range) 1.1 ± 0.4 (0-2)
EDSS*, mean ± SD, [median], (range) 1.7 ± 1.1, [2], (0-5)
Immunomodulatory therapy, n(%) 44 (67)
They have had children, n (%) 32 (53)
EDSS* = Expanded Disability Status Scale; SD = Standard Deviation.
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sion in the study (Table 2).
Overall, the mean values for the different blood chem-
istry analyses performed on the population were normal,
showing a significant dispersion and wide ranges.
The frequency of serological and genetic markers was
compared to the findings in the control group. Histolo-
g i c a ld u o d e n a lb i o p s i e sw e r em a d ei no n l yR R M S
patients and their results are shown in Table 3.
Age, sex, anti-TGt2 values, genetic and histologic
characteristics of the eight cases diagnosed with simulta-
neous celiac disease, which showed slight increased ser-
ologic levels of TGt-2 and diverse degrees of villous
atrophy are shown in Table 4.
The clinical characteristics of the eight patients with
associated celiac disease refered to the presence of gas-
trointestinal symptoms were found in 6 (75%); weight
loss was observed in 1 patient (12.5%). The main neuro-
logic form was myelitis in 4 (50%) and mixed in 4
(50%). No ataxia forms of presentation were found.
Three patients (37.5%) were treated with interferon-
beta. We found 2 patients (25%) with ANAs (+). All
these data are shown in Table 5.
A l lt h ec e l i a cp a t i e n t sw e r ep u to nag l u t e nf r e ed i e t
and all of them improved considerably both with respect
to the gastrointestinal and to the neurological sympto-
matology in the follow-up period.
The only differential parameter between celiacs and
non-celiacs was the age of onset of MS, that was
younger (35 ± 7 y.o) in the former and older (44 ± 10 y.
o) in the latter (p < 0.05)
We have observed a high frequency of several different
related diseases. Dermatitis: 41 (57%); Iron deficiency
anemia: 28 (39%); Liver function test alterations: 18
(25%); Recurrent urinary tract infections: 12 (17%);
Osteoporosis: 4 (6%) (Figure 1).
It is significant that a high prevalence of CD was
found in first-degree relatives of RRMS patients, with 23
(32%) positive cases among the 126 studied individuals.
We also discovered a variety of associated circulating
auto-antibodies in these patients, the most frequently
observed being anti-thyroid peroxidase (anti-TPO) anti-
bodies, followed by anti-nuclear antibodies (ANA), and,
less frequently, anti-mitochondrial antibodies (AMA).
Their percentages are shown in Figure 2.
Discussion
Our data support the hypothesis that there is an
increased prevalence of serological markers of CD in
RRMS patients (OR: 5.33; CI-95%: 1.07-26.45). Never-
theless, we have not found any differences between the
DQ2 and DQ8 genetic markers in the patient and con-
trol groups. We also discovered several duodenal lesions
in 21 (29%) of RRMS patients and mild villous atrophy
in 8 (11.1%) of them.
All of these findings, together with the high prevalence
of CD in first-degree relatives (32%) support a frequent
association with gluten intolerance in RRMS patients.
These results have been observed by other authors from
Israel [18]. The specific role of serological gluten markers
in the pathogenesis of multiple sclerosis remains uncertain.
MS is a disorder presumed to be of autoimmune nature,
characterized by a chronic demyelinating inflammatory
process which affects the CNS, but its etiology remains
unknown. MS affects mainly Caucasians, predominantly
women, and in most cases, appears in young adulthood.
Genetic, immunopathologic and environmental factors
Table 2 Paraclinical tests of RRMS patients (n = 72)
CSF oligoclonal bands
1, n (%) 51 (71)
Altered VEPs
2 +, n (%) 46 (64)
Altered SEPs
3+, n (%) 52 (72.2)
T1-weighted gadolinium-enhanced MRI
4 lesions, n
5 (%) 25 (35)
T2-MRI supratentorial lesions, mean ± SD (range) 4.6 ± 6.5 (6-30)
T2-MRI infratentorial lesions, mean ± SD (range) 1.6 ± 2.5 (0-10)
T2-MRI medullar lesions, mean ± SD (range) 1.2 ± 1.4 (0-6)
1CSF = Cerebrospinal fluid;
2VEPs = Visual evoked potentials;
3SEP =
Somatosensory evoked potentials;
4MRI = Magnetic Resonance Imaging; n
5 =
number of cases.








2, n [%] 7 (10) 3 (2.4) < 0.05
HLA-DQ2
3 (+), n [%] 21 (29) 32 (26) NS
5
HLA-DQ8 (+), n (%) 8 (11) 17 (14) NS
Villous atrophy (Marsh 3), n (%) 8 (11) ND
4 NS
1CD = Celiac Disease;
2Anti-tTG2 = Anti-tissue transglutaminase-2 antibodies
3HLA = Human leukocyte antigens;
4ND = Not done;
5NS = Not significant.
Table 4 Demographic, serological, genetic and
histological characteristics of the eight patients
exhibiting an associated CD









1 33 187 (+) ND
3 3b
2 F 28 10.3 (+) ND 3a
3 F 25 8.5 (+) ND 3a
4 F 27 4.2 (+) ND 3a
5 F 26 9.4 (+) ND 3b
6 F 29 2.8 (+) ND 3a
7 F 23 3.6 (-) (+) 3a
8 F 34 1.8 (+) ND 3a
1F = Female;
2Marsh = Histological classification of duodenal biopsies for CD;
3ND = Not done.
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mechanisms that remain poorly understood [19].
Celiac disease (CD) is a systemic autoimmune disorder
with a well-defined etiology. It appears as a consequence
of permanent gluten intolerance, which occurs in geneti-
cally predisposed individuals. CD affects primarily, but
not exclusively, the small intestine. It can start at any
age, both during childhood or adolescence, and it often
appears in adulthood [9]. Currently known genetic mar-
kers are excellent predictors of propensity for CD, but a
small proportion of patients (5-10%) are negative for
both DQ2 and DQ8, suggesting that other genetic mar-
kers of CD are yet to be described. Good candidates are
additional HLA class I markers, including MICA and
MICB, as well as other non-HLA markers detected by
GWAS studies [20].
Until about two decades ago, CD was considered a rare
disease, but it has now been shown to be very common,
with a fairly uniform worldwide distribution and an aver-
a g ep r e v a l e n c eo f1 - 2 % ,a l t h o u g ht h i sd i s e a s ei so f t e n
underestimated, and therefore under-diagnosed [21].
Individuals predisposed to CD exhibit inappropriate
immune response to peptides derived from wheat, bar-
ley, and rye prolamins. Although several immunogenic
epitopes are present in gluten, the most powerful is a
peptide of 33 amino acids (residues 57-89), contained in
the a-gliadin fraction of gluten. This peptide is rich in
proline and glutamine residues and appears to be pri-
marily responsible for gluten toxicity, making it the
main pathogenic factor linked to the occurrence of the
disease [22].
During the pathogenesis leading to the appearance of
lesions in the small intestine, gliadin peptides cross the
intestinal epithelium and, at the level of the submucosa,
they are modified by tissue transglutaminase (TGt2).
Deamidated peptides are presented to dendritic cells
with HLA-DQ2/DQ8 receptors, which in turn present
them to CD4+ cells which, when activated, release cyto-
kines such as Interferon-gamma (IFN-g) and other med-
iators of inflammation. The characteristic histological
changes, inflammation and/or villous atrophy, occur in
the small intestinal mucosa [23,24].
Table 5 Clinical characteristics of the eight patients with associated CD
Patients Gastrointestinal symptoms Weight loss Neurological syndrome IFN-beta treatment Dermatitis ANA (+)
1 Diarrhea Yes Myelitis No Yes No
2 None No Myelitis Yes No Yes
3 GERD+Constipation No Optical neuritis No Yes Yes
4 Constipation No Encephalitis No No No
5 GERD No Myelitis No Yes No
6 Constipation No Encephalitis Yes No No
7 GERD+Constipation No Optical neuritis No No No
8 None No Myelitis Yes Yes No
GERD = Gastroesophageal Reflux Disease; ANA = Antinuclear antibody test.
Figure 1 Percentages of individuals who scored positive for
several associated conditions are shown. IDA = Iron Deficiency
Anemia; LFTs = Liver Function Tests; UTIs = Urinary Tract Infections.
Figure 2 Frequency of associated auto-antibodies found in all
MS patients. Anti-TPO = Anti-thyroid peroxidase antibodies; ANAs
= Anti-nuclear antibodies; AMAs = Anti-mitochondrial antibodies.
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taminase type 2 (TGt-2) is the self-antigen that reacts
against endomysium antibodies (EMA). This must to be
evaluated only by using indirect immunofluorescence
technique on monkey esophageal epithelium. The deter-
mination of human antibody reactive against TGt-2 has
the same diagnostic value as the EMA, but has a greater
clinical utility, because it can be achieved with simpler
techniques (commercial ELISA). Such diagnostic meth-
ods were found to allow for high sensitivity and specifi-
city (close to 90%) in the various studies carried out in
the early years after their commercialization [25].
As the determination of anti-TGt-2 antibodies became
used more routinely, a marked decrease of sensitivity was
found to exist when studying patients without villous
atrophy (or with a mild degree, as normally happens in
adults). Several published studies among large groups of
celiac patients, have clearly demonstrated that a positive
anti-TGt-2 antibody test, correlates linearly with the
degree of severity of the histological duodenal lesions
found. In patients presenting only lymphocytic enteritis
(Marsh I), its sensitivity is very low, between 15-30% at
best [26-28]. These findings have led to the application of
new diagnostic strategies, such as the concurrent use of
genetic testing, or the determination of anti-TGt-2 anti-
bodies in duodenal aspirate in cases of negative serology.
An alternative approach to increasing sensitivity relies on
the use of a corrected threshold for positivity; its value
has been recommended as 2 U/ml for adults [15,29].
This is the threshold that we have applied in the present
study. We did not employ EMA antibodies, because they
measure the same substract than the anti-TGt-2 and the
anti-gliadin, because they have a lower sensitivity and
specificity than the anti-TGt-2 used.
The findings from duodenal biopsies are still consid-
ered by most experts as the “cornerstone” or the “gold
standard” for diagnosis of CD. However, this statement
emphatic as it may sound, is currently being challenged,
especially if we take into account the adult forms of CD.
In cases with very high levels of anti-TGt-2 antibodies
(>100 U/ml), the duodenal biopsy may be avoided, since
in most cases (> 90%) such high levels are associated
with the presence of villous atrophy [30]. When the his-
tological results are normal, but the serology is positive
and the clinical picture is suggestive of CD, the diagnostic
uncertainty remains, and in such cases a gluten-free diet
(GFD) could be recommended for at least 6 months,
before definitely ruling out a CD.
When this diagnosis is dubious, it could be useful to per-
form a genetic and familial study such as those we carried
out in the present study. While the prevalence of DQ2 in
the general population is 20-40%, it reaches 90% among
celiac patients, as confirmed in a study by Fernández-
Bañares et al., in which a series of patients with presumed
irritable bowel syndrome and predominant diarrhea were
screened for possible CD [31]. The determination of the
known genetic markers for celiac disease (DQ2 and DQ8)
therefore, has a high negative predictive value.
I nt h ep r e s e n ts t u d yw eh a v ef o u n dah i g hp r e v a l e n c e
of celiac disease among MS patients (11.1%) based
mainly on the presence of villous atrophy in the duode-
nal biopsy. This is between 5-10 times higher that the
frequency found in the general population. All the 8
celiac patients were female. Six had gastrointestinal
symptoms, with predominant constipation in 5 and
chronic gastro-esophageal reflux disease (GERD), in 3.
Surprisingly only one patient had chronic diarrhoea and
weight loss. This form is called “atypical presentation”
and is common in adults, in contrast to the “classical
form” that predominates in children. The response of
the gluten-free diet was excellent in all of them, both
from the digestive and the neurologic point of view in
the average follow-up period of three years long.
The predominant neurologic clinical presentation on
these celiac patients was myelitis in 4, and mixed in the
rest. No ataxic forms were found. No specific findings
were seen on their MRI’s compared with non-celiac
patients.
Only 3 celiac patients were treated with IFN beta 1-b,
and we didn’t find any more autoimmune disturbances in
them. The remaining 5 CD patients, were only on a GFD.
We performed a family screening study in all the 72 MS
patients, not only in the 8 celiacs, and we found a very
high prevalence of CD among them, with a total of 23 first
degree relatives positive among 126 screened (32%)
CD is also associated with several neurological con-
ditions at a significantly higher frequency than in the
general population, as can be observed in patients with
migraine [32,33]. Cerebellar ataxia associated with glu-
ten is the syndrome most commonly associated with
CD, especially in adult patients. Many immunopatho-
genic mechanisms and different antibodies associated
with gluten have been described which are capable of
crossing the blood-brain barrier and deposit at the
level of the Purkinje cells, where they produce a
marked inflammatory response followed by neuronal
degeneration and cerebellar atrophy [34,35]. An isoen-
zyme of TGt has been recently described, specifically
the subtype 6, which is present in the cerebellum of
patients with CD-associated ataxia, and its positivity
would be useful in explaining the pathogenesis of this
process [36].
Conclusions
In this prospective series of 72 RRMS patients, we have
found at least 8 (11.1%) with a related CD, confirmed by
the presence of serological antibodies (TGt-2) in 7 and
villous atrophy in all of them. This represents a
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in this group of patients than that found of the general
population.
A gluten-free diet should be considered for any RRMS
patient, who exhibits these serological and histological
findings, characteristic of the presence of an associated
celiac disease.
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